Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Simon

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Leukemia|July 1, 2020
COVID-19 among fit patients with CLL treated with venetoclax-based combinationsMoritz Fürstenau, Petra Langerbeins, Nisha De Silva, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Leukemia|July 1, 2020
COVID-19 among fit patients with CLL treated with venetoclax-based combinationsMoritz Fürstenau, Petra Langerbeins, Nisha De Silva, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Leukemia & Lymphoma|March 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemiaFlorian Simon, Rudy Ligtvoet, Moritz Fürstenau, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Pageof 11